The Mayo Clinic has received a patent for a new medication selection procedure. GeneSight uses a test to prioritize the selection of medications for patients with depression, chronic pain and other psychiatric disorders.
GeneSight tests for genetic variants that affect a patient’s response to psychotropic and analgesic medications, allowing clinicians to make evidence-based decisions about drug selection.
The company said the tool should help skilled nursing facilities reduce their use of antipsychotics.
